Literature DB >> 636957

Surface activation of factor XII (Hageman factor)--critical role of high molecular weight kininogen and another potentiator).

J Y Chan, C E Burrowes, H Z Movat.   

Abstract

When factor XII was adsorbed to kaolin it slowly became activated and converted prekallikrein to kallikrein. In the presence of HMW-kininogen the rate of activation of factor XII and consequently that of prekallikrein was markedly enhanced. The enhancing effect of HMW-kininogen was a dose-dependent phenomenon. In order to enhance the activation of factor XII on a surface the HMW-kininogen molecule had to be intact. Cleavage of HMW-kininogen by kallikrein decreased the enhancing effect of HMW-kininogen, there being an inverse relation between the bradykinin-generated and the capacity to enhance factor XII activation. Another 'potentiator' of factor XII activation was isolated from proteins adsorbed to aluminum hydroxide. This potentiator further increased the activation of factor XII, also in a dose-dependent fashion. It was postulated that factor XII is slowly converted into its active form by exposure to negatively charged surfaces; that this process is enhanced by kallikrein and further accelerated by HMW-kininogen and the 'potentiator'; and that these enhancing substances probably act by opening active sites on the factor XII molecule.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 636957     DOI: 10.1007/bf01972404

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  29 in total

1.  Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.

Authors:  R T Matheson; D R Miller; M J Lacombe; Y N Han; S Iwanaga; H Kato; K D wuepper
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

2.  Isolation of antithrombin III from human plasma: its separation from alpha1-antitrypsin1.

Authors:  C E Burrowes; H Z Movat
Journal:  Biochem Biophys Res Commun       Date:  1977-01-10       Impact factor: 3.575

3.  Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII.

Authors:  S Schiffman; P Lee
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

4.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

5.  Activation of factor XII (Hageman factor): enhancing effect of a potentiator.

Authors:  J Y Chan; C E Burrowes; H Z Movat
Journal:  Thromb Res       Date:  1977-02       Impact factor: 3.944

6.  The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors.

Authors:  J Y Chan; C E Burrowes; F M Habal; H Z Movat
Journal:  Biochem Biophys Res Commun       Date:  1977-01-10       Impact factor: 3.575

7.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

8.  Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis.

Authors:  V H Donaldson; H I Glueck; M A Miller; H Z Movat; F Habal
Journal:  J Lab Clin Med       Date:  1976-02

9.  The kinin system of human plasma. IV. The interrelationship between the contact phase of blood coagulation and the plasma kinin system in man.

Authors:  A H Ozge-Anwar; H Z Movat; J G Scott
Journal:  Thromb Diath Haemorrh       Date:  1972-02-29

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.